EAM
FRTX

Eventide Asset Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Eventide Asset Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-952
Closed -$345K – 152
2018
Q2 		$345K Sell
952
-4,445
-82% -$2.09M 0.01% 143
2018
Q1 		$2.46M Hold
5,397
– – 0.12% 105
2017
Q4 		$3.11M Buy
+5,397
New +$3.56M 0.16% 93

Other funds holding FRTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eventide Asset Management's FRTX Position: Q3 2018 in Review

Eventide Asset Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2018, closing a stake of 952 shares — an estimated $345K sold.

Eventide Asset Management first reported a position in FRTX in Q4 2017 and held it in 3 quarters. The position peaked at $3.11M in Q4 2017. 32 funds tracked by Wall St. Rank hold FRTX as of Q3 2018.

  • Eventide Asset Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Eventide Asset Management sold 952 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $345K.
  • Eventide Asset Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q4 2017 and held it in 3 quarters.
  • Eventide Asset Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $3.11M in Q4 2017.
  • 32 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Eventide Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.